640,558 Shares in AbbVie Inc. $ABBV Purchased by Nykredit A S

Nykredit A S acquired a new position in shares of AbbVie Inc. (NYSE:ABBV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 640,558 shares of the company’s stock, valued at approximately $161,190,000.

A number of other large investors also recently made changes to their positions in the business. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie during the fourth quarter worth approximately $28,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% in the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after buying an additional 45 shares in the last quarter. Burk Holdings LLC acquired a new stake in shares of AbbVie during the 2nd quarter valued at $30,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie during the 4th quarter valued at $31,000. Finally, Abound Financial LLC purchased a new position in shares of AbbVie during the 4th quarter valued at $32,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Stock Up 0.9%

Shares of AbbVie stock opened at $251.04 on Thursday. The stock has a market capitalization of $443.53 billion, a P/E ratio of 70.92, a PEG ratio of 1.13 and a beta of 0.29. The stock has a 50 day moving average price of $254.66 and a two-hundred day moving average price of $230.55. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the company posted $2.97 earnings per share. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, August 14th. Investors of record on Wednesday, July 15th were issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 2.8%. The ex-dividend date was Wednesday, July 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABBV. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, August 4th. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 target price for the company in a research note on Thursday, August 13th. Wells Fargo & Company increased their price target on shares of AbbVie from $295.00 to $300.00 and gave the stock an “overweight” rating in a research note on Monday, August 17th. HSBC restated a “buy” rating and set a $300.00 price target on shares of AbbVie in a report on Monday, July 6th. Finally, BNP Paribas Exane upped their price objective on shares of AbbVie from $218.00 to $247.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $275.95.

Insiders Place Their Bets

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.